Literature DB >> 15295608

Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.

M Malec1, V H J van der Velden, E Björklund, J M Wijkhuijs, S Söderhäll, J Mazur, M Björkholm, A Porwit-MacDonald.   

Abstract

Detection of minimal residual disease (MRD) in follow-up samples from patients with ALL is essential for evaluation of treatment response. We applied multicolor flow cytometry and real-time quantitative PCR (RQ-PCR) to compare MRD results in 71 follow-up samples from 22 children treated for ALL. When results obtained by flow cytometry and RQ-PCR were grouped into positive-negative categories, a significant level of agreement was found in 72% of samples (P<0.001). However, if a cutoff level of 0.01% was applied, the concordance was 89%. MRD could be quantified in 19 samples by both methods, showing a strong correlation (P<0.01). Nevertheless, MRD levels differed more than five-fold between both methods in 4/19 samples. In 20 (28%) samples, the two techniques showed discordant results. Most discordant results (17/20) were due to the limited sensitivity of flow cytometry analysis within the range 0.01-0.001%; remaining discordant results were due to the instable or subclonal IG/TCR gene rearrangements or a limited quantitative range of the applied RQ-PCR targets. Although concordant results could be obtained by flow cytometry and RQ-PCR analysis, MRD levels may differ. Therefore, MRD data obtained by these two techniques are not yet easily exchangeable.

Entities:  

Mesh:

Year:  2004        PMID: 15295608     DOI: 10.1038/sj.leu.2403444

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

1.  Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.

Authors:  Nina F Øbro; Lars P Ryder; Hans O Madsen; Mette K Andersen; Birgitte Lausen; Henrik Hasle; Kjeld Schmiegelow; Hanne V Marquart
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

3.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Authors:  Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

4.  Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Authors:  Giuseppe Gaipa; Giovanni Cazzaniga; Maria Grazia Valsecchi; Renate Panzer-Grümayer; Barbara Buldini; Daniela Silvestri; Leonid Karawajew; Oscar Maglia; Richard Ratei; Alessandra Benetello; Simona Sala; Angela Schumich; Andre Schrauder; Tiziana Villa; Marinella Veltroni; Wolf-Dieter Ludwig; Valentino Conter; Martin Schrappe; Andrea Biondi; Michael N Dworzak; Giuseppe Basso
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

5.  Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.

Authors:  Aaron C Logan; Nikita Vashi; Malek Faham; Victoria Carlton; Katherine Kong; Ismael Buño; Jianbiao Zheng; Martin Moorhead; Mark Klinger; Bing Zhang; Amna Waqar; James L Zehnder; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-24       Impact factor: 5.742

6.  Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.

Authors:  Leonid Karawajew; Michael Dworzak; Richard Ratei; Peter Rhein; Giuseppe Gaipa; Barbara Buldini; Giuseppe Basso; Ondrej Hrusak; Wolf-Dieter Ludwig; Günter Henze; Karl Seeger; Arend von Stackelberg; Ester Mejstrikova; Cornelia Eckert
Journal:  Haematologica       Date:  2015-05-22       Impact factor: 9.941

7.  Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Authors:  Olga Sala Torra; Megan Othus; David W Williamson; Brent Wood; Ilan Kirsch; Harlan Robins; Lan Beppu; Margaret R O'Donnell; Stephen J Forman; Frederick R Appelbaum; Jerald P Radich
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-03       Impact factor: 5.742

8.  Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  Mariana Tomazini Pinto; Tathiane Maistro Malta; Evandra Strazza Rodrigues; Daniel Guariz Pinheiro; Rodrigo Alexandre Panepucci; Kelen Cristina Ribeiro Malmegrim de Farias; Alessandra De Paula Sousa; Osvaldo Massaiti Takayanagui; Yuetsu Tanaka; Dimas Tadeu Covas; Simone Kashima
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-16       Impact factor: 2.205

9.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

10.  Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology.

Authors:  Sona Peková; Ludmila Bezdícková; Lukás Smolej; Tomás Kozák; Ivana Hochová; Pavel Zák; Lucie Tomsíková; Miroslav Průcha
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.